XBP1 as a novel molecular target to attenuate drug resistance in hepatocellular carcinoma-Reference-Cited by-同舟云学术

XBP1 as a novel molecular target to attenuate drug resistance in hepatocellular carcinoma

Published:2023-12-02 Issue:12 Volume:27 Page:1207-1215
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Hendi Zahra¹²,Asadi Sarabi Pedram¹,Hay David³,Vosough Massoud¹⁴

Affiliation:

1. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran

2. Department of Animal Biology-Cell and Developmental, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran

3. Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh BioQuarter, Edinburgh, UK

4. Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital-Huddinge, Huddinge, Sweden

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2023.2293746

Reference82 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach

3. Therapeutic options in hepatocellular carcinoma: a comprehensive review

4. Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights

5. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight